🚀 VC round data is live in beta, check it out!
Savara Valuation Multiples
Discover revenue and EBITDA valuation multiples for Savara and similar public comparables like Neuren Pharma, Septerna, ACROBiosystems, Inventiva and more.
Savara Overview
About Savara
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Founded
1995
HQ
Employees
59
Website
Sectors
Financials (LTM)
EV
$1B
Savara Financials
Savara reported last 12-month revenue of $4M.
In the same LTM period, Savara generated $3M in gross profit and had net loss of ($119M).
Revenue (LTM)
Savara P&L
In the most recent fiscal year, Savara reported revenue of — and EBITDA of ($123M).
Savara expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $3M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($123M) | XXX | XXX | XXX |
| EBIT Margin | (3471%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($119M) | XXX | ($119M) | XXX | XXX | XXX |
| Net Margin | (3333%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Savara Stock Performance
Savara has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Savara's stock price is $6.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $-0.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSavara Valuation Multiples
Savara trades at 315.3x EV/Revenue multiple, and (9.2x) EV/EBITDA.
EV / Revenue (LTM)
Savara Financial Valuation Multiples
As of March 21, 2026, Savara has market cap of $1B and EV of $1B.
Equity research analysts estimate Savara's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Savara has a P/E ratio of (10.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 315.3x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (9.2x) | XXX | XXX | XXX |
| EV/EBIT | (9.1x) | XXX | (9.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 371.0x | XXX | — | XXX | XXX | XXX |
| P/E | (10.3x) | XXX | (10.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (11.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Savara Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Savara Margins & Growth Rates
Savara's revenue in the last 12 month grew by 713%.
Savara's revenue per employee in the last FY averaged $0.1M.
Savara Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 713% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 20% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1280% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2270% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Savara Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Neuren Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Septerna | XXX | XXX | XXX | XXX | XXX | XXX |
| ACROBiosystems | XXX | XXX | XXX | XXX | XXX | XXX |
| Inventiva | XXX | XXX | XXX | XXX | XXX | XXX |
| CStone Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Savara M&A Activity
Savara acquired XXX companies to date.
Last acquisition by Savara was on XXXXXXXX, XXXXX. Savara acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Savara
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSavara Investment Activity
Savara invested in XXX companies to date.
Savara made its latest investment on XXXXXXXX, XXXXX. Savara invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Savara
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Savara
| When was Savara founded? | Savara was founded in 1995. |
| Where is Savara headquartered? | Savara is headquartered in United States. |
| How many employees does Savara have? | As of today, Savara has over 59 employees. |
| Who is the CEO of Savara? | Savara's CEO is Matthew Pauls. |
| Is Savara publicly listed? | Yes, Savara is a public company listed on Nasdaq. |
| What is the stock symbol of Savara? | Savara trades under SVRA ticker. |
| When did Savara go public? | Savara went public in 1996. |
| Who are competitors of Savara? | Savara main competitors are Neuren Pharma, Septerna, ACROBiosystems, Inventiva. |
| What is the current market cap of Savara? | Savara's current market cap is $1B. |
| What is the current revenue of Savara? | Savara's last 12 months revenue is $4M. |
| What is the current revenue growth of Savara? | Savara revenue growth (NTM/LTM) is 713%. |
| What is the current EV/Revenue multiple of Savara? | Current revenue multiple of Savara is 315.3x. |
| Is Savara profitable? | No, Savara is not profitable. |
| What is the current net income of Savara? | Savara's last 12 months net income is ($119M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.